KIT and gastrointestinal stromal tumor: In an effort to develop combinatorial therapies to decipher drug resistance, Gupta et al. investigated the use of KIT/PI3K/MAPK (KPM) pathways as potential targeted therapy for gastrointestinal stromal tumors (GIST).